Merck & Co. Inc. (MRK) Initiates Phase 3 Trial on Breast Cancer Drug

Merck & Co., Inc. (NYSE:MRK) is one of the cheap blue-chip stocks to invest in now. On August 27, the company confirmed it has initiated the HERTHENA-Breast04 phase 3 clinical trials in partnership with Daiichi Sankyo.

Dosing of the first patient with patritumab deruxtecan for metastatic hormone receptor-positive, HER2-negative breast cancer has already started. The randomized trial is to evaluate patritumab deruxtecan against the physician’s choice of treatment in patients with an advanced metastatic cancer.

The trial aims to enroll 1,000 patients across Asia, Europe, North America, and South America. Its dual primary endpoints are progression-free survival, as determined by blinded independent central review, and overall survival.

In 2023, Merck entered into a collaboration agreement with Daiichi Sankyo to jointly develop and commercialize patritumab deruxtecan and other antibody drug conjugates.

Merck & Co., Inc. (NYSE:MRK) is a global science and technology company that operates in three main business areas: Healthcare, focusing on developing innovative therapies for diseases; Life Science, providing tools and services for scientific research and biotech production; and Electronics, creating materials for the semiconductor and display industries.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Robinhood Stocks to Buy Right Now and 13 Best Long-Term Stocks to Invest in According to Warren Buffett.

Disclosure: None. This article is originally published at Insider Monkey.